]>
IRCT2015031221420N2 IRCT 2015-06-25 shahid sadoughi university of medical sciences Dual triggering in improving assisted reproductive programs outcome A comparison of Dual triggering by administration of Gonadotropin releasing hormon agonist plus human chorionic gonadotropin versus HCG in normal responders at assisted reproductive programs outcome 2014-03-01 anticipated 223 Complete https://irct.ir/trial/18778 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: randomization was done by table of random numbers, Blinding description: Patients were named as groups 1 and 2. And the statistical analyzer did not know the type of treatment protocol used in each group. 2 female infertility. Intervention 1: control group receive 6500 I.U hCG IM for triggering final oocyte maturation . Intervention 2: Intervention group receive 6500 I.U. IM hCG+triptorelin0.2mg/sc for triggering. Abstract Background: Gonadotropin-releasing hormone agonists (GnRH-a) was increasingly used for triggering oocyte maturationfor the prevention of ovarian hyperstimulation syndrome. Studies suggest that GnRH-a might be used as a better trigger agent since it causes both Luteinizing hormone and follicle stimulating hormone release from a physiologic natural cycle. Objective: The aim of this study was to evaluate the effect of dual-triggering in assisted reproductive technology outcomes. Materials and Methods: 192 normal responder women aged ≤42 years and 18< Body Mass Index <30 kg/m2 enrolled in this single-blind randomized controlled trial. All participants received antagonist protocol. For final triggering, women randomly were divided into two groups. Group, I was triggered by 6500 IU human chorionic gonadotropin (hCG) alone, and group II by 6500 IU hCG plus 0.2 mg of triptorelin. The implantation, chemical, clinical and ongoing pregnancy, and abortion rates were measured. Results: The mean of retrieved oocytes and obtained embryos were statistically higher in the dual-trigger group (group I), but the implantation and pregnancy rates were similar in two groups. Conclusion: The results of our study did not confirm the favorable effect of dual-triggered oocyte maturation with a GnRH-a and a standard dosage of hCG as an effective strategy to optimize pregnancy outcome for normal responders in GnRH-antagonist cycles. We think that this new concept requires more studies before becoming a universal controlled ovarian hyperstimulation protocol in in vitro fertilization practice. Yes - There is a plan to make this available What will be shared: All participant data sets are to be shared When: 2 months after the result publication To whom: A journal in which the results are published Conditions: Submission of an official application via the agent that is legally in charge Where to obtain: Yazd Reproductive Sciences Institute How to obtain: Submission of an official application Comments:
public Maryam Eftekhar
Bouali Avenue, Safayeh
Yazd Iran (Islamic Republic of) 8916877391 +98 35 3824 7085 eftekhar@ssu.ac.ir Yazd University of Medical Sciences scientific Maryam Eftekhar
Bouali Avenue, Safayeh
Yazd Iran (Islamic Republic of) 8916877391 +98 35 3824 7085 eftekhar@ssu.ac.ir Yazd University of Medical Sciences Iran (Islamic Republic of) normal responder women by tubal or male infertility factor, 18< Body mass index <30 kg/m2, and age ≤42 yr with the history of infertility for at least 1 yr that were candidate for ART protocol no limit 42 years Female the presence of endocrine disorders such as diabetes mellitus, hyperprolactinemia, thyroid disorders, congenital adrenal hyperplasia, Cushing syndrome, polycystic ovary syndrome, congenital uterine anomaliesdisorders, repeated implantation failure, day-3 FSH concentration ≥10 IU/L or serum anti-Mullerian hormone ≤1.0 ng/mL, and azoospermia N97.9 Female infertility, unspecified Treatment - Drugs Treatment - Drugs control group receive 6500 I.U hCG IM for triggering final oocyte maturation . Intervention group receive 6500 I.U. IM hCG+triptorelin0.2mg/sc for triggering. Clinical pregnancy rate. Timepoint: 28 days after transfer. Method of measurement: vaginal sonography. Chemical pregnancy rate. Timepoint: 14 days after transfer. Method of measurement: BhCG test. shahid sadoughi university of medical sciences Approved 2014-06-22 Yazd Research and Clinical Center for infertility Bouali Avenue, Safayeh yazd Yazd Iran (Islamic Republic of)